title: Sphingosine lysolipids in the CNS: endogenous cannabinoid antagonists or a parallel pain modulatory system?
abstract: A significant number of patients experience chronic pain and the intractable side effects of currently prescribed pain medications. Recent evidence indicates important pain-modulatory roles for two classes of G-protein-coupled receptors that are activated by endogenous lipid ligands, the endocannabinoid (eCB) and sphingosine-1-phosphate (S1P) receptors, which are widely expressed in both the immune and nervous systems. In the central nervous system (CNS), CB1 cannabinoid and S1P1 receptors are most abundantly expressed and exhibit overlapping anatomical distributions and similar signaling mechanisms. The eCB system has emerged as a potential target for treatment of chronic pain, but comparatively little is known about the roles of S1P in pain regulation. Both eCB and S1P systems modulate pain perception via the central and peripheral nervous systems. In most paradigms studied, the eCB system mainly inhibits pain perception. In contrast, S1P acting peripherally at S1P1 and S1P3 receptors can enhance sensitivity to various pain stimuli or elicit spontaneous pain. However, S1P acting at S1P1 receptors and possibly other targets in the CNS can attenuate sensitivity to various pain stimuli. Interestingly, other endogenous sphingolipid derivatives might play a role in central pain sensitization. Moreover, these sphingolipids can also act as CB1 cannabinoid receptor antagonists, but the physiological relevance of this interaction is unknown. Overall, both eCB and sphingolipid systems offer promising targets for the treatment of chronic pain. This review compares and contrasts the eCB and S1P systems with a focus on their roles in pain modulation, and considers possible points of interaction between these systems.
authors.affiliation: Department of Pharmacology and Toxicology and Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA 23298, United States. deselley@vcu.edu
authors.forename: Dana E
authors.initials: DE
authors.lastname: Selley
authors.forename: Sandra P
authors.initials: SP
authors.lastname: Welch
authors.forename: Laura J
authors.initials: LJ
authors.lastname: Sim-Selley
mesh_terms: D000818:Animals; D063387:Cannabinoid Receptor Antagonists / Q000134:cerebrospinal fluid* / Q000494:pharmacology / Q000627:therapeutic use; D002186:Cannabinoids / Q000037:antagonists & inhibitors* / Q000134:cerebrospinal fluid*; D002490:Central Nervous System / Q000187:drug effects / Q000502:physiology*; D063388:Endocannabinoids / Q000134:cerebrospinal fluid* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008246:Lysophospholipids / Q000134:cerebrospinal fluid* / Q000494:pharmacology / Q000627:therapeutic use; D010146:Pain / Q000134:cerebrospinal fluid* / Q000188:drug therapy / Q000503:physiopathology; D013107:Sphingolipids / Q000134:cerebrospinal fluid / Q000494:pharmacology / Q000627:therapeutic use; D013110:Sphingosine / Q000134:cerebrospinal fluid* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D063387:Cannabinoid Receptor Antagonists; D002186:Cannabinoids; D063388:Endocannabinoids; D008246:Lysophospholipids; D013107:Sphingolipids; D013110:Sphingosine
keywords: Antinociception; CB1 receptor; Hyperalgeisa; Sphingosine-1-phosphate